The U.S. Food and Drug Administration (FDA) has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ENTR-601-44, the company’s experimental exon-skipping therapy, in ...

A statistical model that takes clinical and demographic factors into account could help guide treatment decisions in people with relapsing-remitting multiple sclerosis (RRMS) who haven’t yet ...

List your movie, TV & celebrity picks.